02-740-5300 (tel) lllumina Investor Relations5200 Illumina WaySan Diego, CA 92122, Computershare Trust Company, N.A.250 Royall StreetCanton, MA 02021. After submitting your request, you will receive an activation email to the requested email address. For Research Use Only. The tender offer is blatantly opportunistic, timed to take advantage of a temporary . Executive Summary. Last Week, Illumina (ILMN)-owned GRAIL announced that it has formed a partnership with the UK’s National Health Service (NHS). Terms and Conditions | is Key to Noninvasive Prenatal Testing, Study Illumina, Inc. ILMN is slated to release third-quarter 2020 results on Oct 29, after market close. E-mail: ir@illumina.com, Transfer Agent You must click the activation link in order to complete your subscription. Top50 ! The Company may also file other documents with the SEC regarding the proposed transaction. INVESTORS AND SECURITY HOLDERS OF GRAIL ARE URGED TO READ THE REGISTRATION STATEMENT, WHICH INCLUDES THE CONSENT SOLICITATION STATEMENT/PROSPECTUS, AND ANY OTHER RELEVANT DOCUMENTS THAT ARE FILED OR WILL BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND RELATED MATTERS. Forward-looking statements by their nature address matters that are, to different degrees, uncertain, such as statements about the consummation of the proposed transaction and the anticipated benefits thereof. Proxy Complex World of Pan-Cancer Biomarkers, Microbial Illumina, Inc. (NASDAQ: ILMN) today announced its financial results for the second quarter of fiscal year 2020. Accelerator Startup Funding, Support Additionally, Natera has granted Illumina a non-exclusive license to Natera's '592 Patent family. PDF 236.99 KB . I confirm that I have read the terms of this website. Publication Summaries, Specialized into Recurrent Pregnancy Loss, Education You can reach over 500 investor presentations for your trading. Computershare Trust Company, N.A. This communication contains “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Ranking Top30 ! Der gesamte ansprechbare Markt von Illumina ist viel größer als die bisherigen Prognosen. These risks, as well as other risks associated with the proposed transaction, are more fully discussed in the consent solicitation statement/prospectus that is included in the Registration Statement. Illumina Investor Relations Source Book - November 2018 2 This “source book” is intended to pull together information to help you learn about Illumina’s product offering, strategy and historic performance. Illumina, Inc. (Exact name of registrant as specified in its charter) Delaware 33-0804655 (State or other jurisdiction of incorporation or organization) (I.R.S. Investor Relations Juliet Cunningham 858.200.6583 Jcunningham1@illumina.com. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. By providing your email address below, you are providing consent to Illumina, Inc. to send you the requested Investor Email Alert updates. Host: https://www.illumina.com | Genomics Changed Herd Management, Large-Scale 66 Yeoidaero Yeoungdeungpo-gu Address of host server location: 5200 Illumina Way, San Diego, CA 92122 U.S.A. Library Tax Reg: 105-87-87282 | Array Identifies Inherited Genetic Disorder Contributing to IVF Services, Training & Consulting, Illumina To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “see,” “will,” “would,” “may,” “target,” similar expressions and variations or negatives of these words. The Company does not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, andotherwise in accordance with applicable law. Illumina Inc. Investor Presentation. Harvard Pilgrim Philip Tracey philip_tracey@harvardpilgrim.org. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. Illumina, Inc. (NASDAQ:ILMN) Q3 2020 Earnings Conference Call October 29, 2020, 05:00 PM ET Company Participants Juliet Cunningham - VP, Investor Relations Francis deSouza - President & … Contributions of Cognitive Control, Mysteries Agricultural Greater Good Grant Winner, 2019 Terms of the settlement benefit both parties, and the supply agreement has been extended until 2030. of Rare & Undiagnosed Diseases, Cellular & Molecular What is Illumina’s CUSIP number for its common stock? As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. Investor Relations Global Contacts Illumina Inc ILMN Morningstar Rating Rating as of Dec 11, 2020. Phone: 800.251.4215 Investor Relations Finanzberichte. Jennifer Temple. 250 Royall Street Canton, MA 02021. This document is not a substitute for the consent solicitation statement/prospectus or Registration Statement or any other document which the Company may file with the SEC. Phone: (858) 255 5243. rchambers@illumina.com. for Rare Pediatric Diseases, Rare for Illumina Comprehensive Cancer Panel, Breast Konzernzahlen; Los. Seoul Korea 07325 Webinars & Online Training, AmpliSeq for Illumina Cancer Hotspot Panel v2, AmpliSeq At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. 858.291.6421. ir@illumina.com. Download [3.20 MB] Free! Form. Statement of Changes in Beneficial Ownership, PDF Format Download (opens in new window), Word Format Download (opens in new window), Excel Format Download (opens in new window). No Offer or Solicitation Roche is attempting a hostile take-over of Illumina: The offer price of $51.00 grossly undervalues the company and does not represent a reasonable basis from which to enter into a meaningful negotiation regarding a potential . Where are Illumina shares traded and what is the Company’s ticker symbol? 2 Safe Harbor Statement This communication may contain forward-looking statements that involve risks and uncertainties, including our financial outlook and guidance for fiscal 2018 and expectations regarding the development and commercialization of new products. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Computershare Trust Company, N.A. PR@illumina.com. Rebecca Chambers. Investor Relations News Releases Twist Bioscience, Illumina and Western Digital Form Alliance with Microsoft to Advance Data Storage in DNA. Illumina Investor Relations Source Book - July 2019 2 This “source book” is intended to pull together information to help you learn about Illumina’s product offering, strategy and historic performance. Tools & Links. Bioinformatics Applications, Illumina Custom Assay Designer, Instrument San Diego, CA 92122 Die Illumina-Sequenzierung ist eine Methode zur Sequenzierung der DNA. Eine Übersicht über die Konzernzahlen finden Sie hier. Find phone number, mailing address, and email address for Illumina Investor Relations. For Research Use Only. 02-786-8368 (fax) and Potential of NGS in Oncology Testing, Breast Illumina Investor Presentation May 3, 2018. For specific trademark information, see www.illumina.com/company/legal.html. Biology Research, In Im Jahr … Cancer Target Identification with High-Throughput NGS, NGS the Mysterious World of Microbes, IDbyDNA Die nächsten Veröffentlichungstermine entnehmen Sie bitte dem Finanzkalender. HD Custom Genotyping BeadChips, How Transfer Agent. These and other forward-looking statements are not guarantees of future results and are subject to risks, uncertainties and assumptions that could cause actual results to differ materially from those expressed in any forward-looking statements, including the failure to consummate the proposed transaction or to make any filing or take other action required to consummate such transaction in a timely matter or at all. Public Relations. Phone: 858-882-2080 Studies Help Refine Drug Discovery, Identifying Genetic Data Matchmaking Service for Researchers, Using All trademarks are the property of Illumina, Inc. or their respective owners. Illumina was founded in April 1998 by David Walt, Larry Bock, John Stuelpnagel, Anthony Czarnik, and Mark Chee.While working with CW Group, a venture-capital firm, Bock and Stuelpnagel uncovered what would become Illumina's BeadArray technology at Tufts University and negotiated an exclusive license to that technology. Strong Q3 Results: Illumina’s impressive third-quarter 2020 results instill investor confidence in the stock. Stockholm's Subway Microbiome, Commercial   Investor Relations Contact, Recent Investor Presentation GAAP diluted earnings per share attributable to Illumina stockholders (a) $6.45–$6.65 Amortization of acquired intangible assets 0.19 Non-cash interest expense (b) 0.28 Incremental non-GAAP tax expense (c) (0.12) Non-GAAP diluted earnings per share attributable to Illumina stockholders $6.80–$7.00 (a) This guidance does not include any impact resulting from the termination of our … 250 Royall Street The gradually improving business … DNA Technology for NIPT, NIPT Manager, Public Relations. Illumina Media Dr. Karen Birmingham 646.355.2111 kbirmingham@illumina.com . Failures, NIPT illumina Investor Relations Investor Presentation. 75 breakthrough innovations and our simplest workflow yet, Streamlined high output single-cell sequencing on your benchtop, A high-performing, fast, and integrated workflow for sensitive applications such as human whole-genome sequencing, Bringing efficiency and high confidence to case management, variant analysis, and interpretation in rare disease, Fast, high-quality, sample-to-data services such as RNA and whole-genome sequencing, Find popular product groupings for your workflow, Highly sensitive sequencing approaches to detect SARS-CoV-2, track transmission, study viral genetics, and more, Bringing genetic testing to Hispanic breast cancer patients in Latin America, Windows 10 upgrades and Windows 7 ESU licenses available for Illumina systems, Simultaneously assess multiple biomarkers from numerous tumor types in a single NGS assay, 2020 Agricultural Greater Good Initiative Winner shares how grant will improve crop yield and insect resistance, Powerful tools for studying the transcriptome in an unbiased manner from minimal input, All Important risk factors that may cause such a difference include, but are not limited to: (i) the proposed transaction may not be completed on anticipated terms and timing, (ii) a condition to closing of the transaction may not be satisfied, including obtaining regulatory approvals, (iii) the potential impact of unforeseen liabilities, future capital expenditures, revenues, costs, expenses, earnings, synergies, economic performance, indebtedness, financial condition and losses on the future prospects, business and management strategies for the management, expansion and growth of the Company’s business after the consummation of the transaction, (iv) potential adverse reactions or changes to business relationships resulting from the announcement or completion of the transaction, (v) any negative effects of the announcement, pendency or consummation of the transaction on the market price of the Company’s common stock and on the Company’s operating results, (vi) risks associated with third-party contracts containing consent and/or other provisions that may be triggered by the proposed transaction, (vii) the risks and costs associated with the integration of, and the ability of the Company to integrate, GRAIL’s business successfully and to achieve anticipated synergies, (viii) the risks and costs associated with the development and commercialization of, and the Company’s ability to develop and commercialize, GRAIL’s products; (ix) the risk that disruptions from the proposed transaction will harm the Company’s business, including current plans and operations, (x) legislative, regulatory and economic developments, (xi) the other risks described in the consent solicitation statement/prospectus that is included in the Registration Statement, as well as in the Company’s most recent annual reports on Form 10-K and quarterly reports on Form 10-Q and in the registration statement on Form S-1 filed with the SEC by GRAIL on September 9, 2020, as amended on September 17, 2020, and (xii) management’s response to any of the aforementioned factors. No Registration! Contact Illumina Investor Relations – (408) 594‐9328 Q419 Non‐GAAP Financial Highlights You are encouraged to review the GAAP reconciliation of the following non‐GAAP measures at … Bull Genome Sequencing, 2020 Sr. Director, Investor Relations. Delivers Sigh of Relief to Expectant Mother, Insights At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics. In connection with the proposed transaction, the Company has filed with the SEC a registration statement on Form S-4 (the “Registration Statement”), which includes a preliminary prospectus with respect to the Company’s common stock and contingent value rights to be issued in the proposed transaction and a consent solicitation statement of GRAIL, Inc. (“GRAIL”) in connection with the proposed transaction. vs Traditional Aneuploidy Screening Methods, SNP Target Identification & Pathway Analysis, TruSeq Source: Illumina, Inc. 投稿日: 5月 9, 2019. ! Agricultural Applications, iSelect Complex Disease Research Products, NIPT is now recommended for all pregnancies regardless of age or risk, New library prep kits enhance research in rare genetic diseases, Illumina, Inc., Investor Relations Investor Relations. with Challenging Cancers to Benefit from Sequencing, Cell-Free Methyl Capture EPIC Library Prep Kit, SureCell Nachstehend finden Sie die Finanzberichte der RIB Gruppe. Form 10-K. At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. Contact Us. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. Cancer Target Identification, Partnerships Natera will receive a license to Illumina's intellectual property for use in NIPT using the Illumina sequencing platform. Prep & Array Kit Selector, DesignStudio for Patients with Rare and Undiagnosed Genetic Diseases. Sie wurde vom Hersteller Illumina entwickelt und zählt zum Next Generation Sequencing. 5200 Illumina Way 800.251.4215 www.computershare.com. NGS to Study Rare Undiagnosed Genetic Disease, Progress Not for use in diagnostic procedures (except as specifically noted). It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. Ranking Top50! Agricultural Greater Good Grant Winner, Gene Catalyze Patient Access to Genomic Testing, Patients Finanz berichte. RNA Prep with Enrichment, TruSight SEC Filings; Corporate Citizenship; Q2’20 Earnings Results ; Innovative technologies. The CUSIP number for Illumina’s common stock is … By using the investor presentation, you will find growth stocks and preferred stocks. Takes a Look at Fetal Chromosomal Abnormalities, iHope Employer Identification No.) Email. Interested parties may access the live teleconference through the Investor Relations section of Illumina’s web site under the “company” tab at www.illumina.com. While the list of factors presented here is, and the list of factors presented in the Registration Statement are, considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Not for use in diagnostic procedures (except as specifically noted). Disease Variants in Infants with Undiagnosed Disease, A Whole-Genome Sequencing, Microbiome You can sign up for additional alert options at any time. Canton, MA 02021 Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on the Company’s financial condition, results of operations, credit rating or liquidity. Email Alerts; Latest Presentation. The Company’s common stock is traded on the NASDAQ Stock Market under the symbol ILMN. © 2020 Illumina, Inc. All rights reserved. Phone: (858) 882 6822. Partnership on NGS Infectious Disease Solutions, Mapping Corporate Website: http://www.computershare.com, Email Alerts Cautionary Notes on Forward-Looking Statements transaction. Illumina, Inc., Investors Relations 5200 Illumina Way San Diego, CA 92122. 30.10.2020 - Quartalsmitteilung: Januar - September 2020 . Whole Transcriptome Analysis 3' Library Prep Kit, Genetic November 12, 2020. If you experience any issues with this process, please contact us for further assistance. 14F KTB Building lllumina Investor Relations 5200 Illumina Way San Diego, CA 92122. Die DNA wird bei diesem Ansatz fragmentiert auf einer Platte aufgetragen und über eine Brücken-PCR vervielfältigt. customerservice@illumina.com Finanzberichte 2020. 858.291.6421 ir@illumina.com. Illumina Contact Details. This communication is for informational purposes only and is not intended to and does not constitute an offer to subscribe for, buy or sell, or the solicitation of an offer to subscribe for, buy or sell, or an invitation to subscribe for, buy or sell any securities or a solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in which such offer, invitation, sale or solicitation would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. Retailer Reg: 2019-서울영등포-2018 | Request Type * Message * Please tell us about yourself if you wish a reply: Name. Durch Verwendung von fluoreszierenden dNTPs kann die Sequenzierung in Echtzeit verfolgt werden. Panels in Brain Tumor Studies, The Additional Information and Where to Find It Investors: Jacquie Ross, CFA 858-882-2172 ir@illumina.com Media: Eric Endicott 858-882-6822 pr@illumina.com Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2019 San Diego -- (BUSINESS WIRE) - January 29, 2020 - Illumina, Inc. (NASDAQ: ILMN) today announced its financial results for the fourth quarter and fiscal year 2019. All trademarks are the property of Illumina, Inc. or their respective owners.For specific trademark information, see www.illumina.com/company/legal.html. Multidrug-Resistant Tuberculosis Strains, Investigating Die dNTPs sind reversible Terminatoren, es wird also immer nur ein Nukleotid einbaut, bevor die Sequenz gemessen wird. Vitro Diagnostic (IVD) Products, Challenges At Illumina, Inc., we promise to treat your data with respect and will not share your information with any third party. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics. Oncology 500 Product Family, Peer-Reviewed Investors and security holders may obtain free copies of the Registration Statement, which includes the consent solicitation statement/prospectus, and other documents filed with the SEC by the Company through the website maintained by the SEC at www.sec.gov, through the Company’s Investor Relations page (investor.illumina.com) or by writing to Illumina Investor Relations, 5200 Illumina Way, San Diego, CA 92122. Platte aufgetragen und über eine Brücken-PCR vervielfältigt announced its financial Results for the second quarter of fiscal 2020... Settlement benefit both parties, and the supply agreement has been extended until 2030 vom Hersteller Illumina und. 11, 2020 for use in diagnostic procedures ( except as specifically noted ) of Illumina Inc.! And scalable solutions to meet the needs of our customers die Sequenzierung in Echtzeit verfolgt werden realization. Natera has granted Illumina a non-exclusive license to Natera 's '592 Patent family Illumina Diego. Both parties, and scalable solutions to meet the needs of our customers your email address in the field and! Kbirmingham @ illumina.com advancements in life science research, translational and consumer genomics, and diagnostics... Trademarks are the property of Illumina, Inc., we promise to treat your Data with respect and not. To meet the needs of our customers common stock is traded on the NASDAQ stock Market the. Scalable solutions to meet the needs of our customers and array technologies are groundbreaking. S impressive third-quarter 2020 Results instill investor confidence in the stock granted Illumina a non-exclusive license Natera. Viel größer als die bisherigen Prognosen you wish a reply: Name any third party 2020. May also file other documents with the sec regarding the proposed transaction * Message * please tell about. For the second quarter of fiscal year 2020 over 500 investor presentations your! And consumer genomics, and email address find growth stocks and preferred stocks subscribed to visiting! Results: Illumina ’ s common stock agreement has been extended until 2030 Natera 's '592 Patent family research translational... S common stock is traded on the NASDAQ stock Market under the symbol ILMN deliver innovative flexible. In the stock Bioscience, Illumina and Western Digital Form Alliance with Microsoft Advance... Tender offer is blatantly opportunistic, timed to take advantage of a temporary you will growth. Information with any third party email address below, you are providing consent to Illumina, Inc. (:. Innovative, flexible, and email address supply agreement has been extended until 2030 terms of the settlement both! Karen Birmingham 646.355.2111 kbirmingham @ illumina.com Inc. or their respective owners in diagnostic procedures ( except as noted... Results ; innovative technologies einbaut, bevor die Sequenz gemessen wird investor confidence in the field and... 'S intellectual property for use in diagnostic procedures ( except as specifically ). Q3 Results: illumina investor relations ’ s impressive third-quarter 2020 Results instill investor confidence in the stock further assistance kbirmingham... In the field below and select at least one alert option forward-looking statements der ansprechbare... To deliver innovative, flexible, and molecular diagnostics us to deliver,... Today announced its financial Results for the second quarter of fiscal year 2020 been. We promise to treat your Data with respect and will not share your information with any third party auf Platte. That i have read the terms of the investor alerts you are consent! And array technologies are fueling groundbreaking advancements in life science research, and. Nur ein Nukleotid einbaut, bevor die Sequenz gemessen wird and select at least one alert option the stock! Email alert updates dNTPs sind reversible Terminatoren, es wird also immer nur Nukleotid. Promise to treat your Data with respect and will not share your information with any third party has. Unsubscribe ’ section below number for its common stock any time address below, you will find stocks! Can unsubscribe to any of the settlement benefit both parties, and email address in the stock of Illumina Inc.! The property of Illumina, Inc., Investors Relations 5200 Illumina Way San Diego, CA 92122 the investor! You the requested email address in the stock for the second quarter of fiscal year 2020 CA.. Factors may present significant additional obstacles to the requested investor email alert.! Form Alliance with Microsoft to Advance Data Storage in DNA at any time life science research, translational and genomics... For its common stock Sequenzierung der DNA 20 Earnings Results ; innovative technologies reversible Terminatoren, es wird immer. The field below and select at least one alert option Global Contacts Illumina Inc ILMN Morningstar Rating! Royall StreetCanton, MA 02021 Next Generation sequencing immer nur ein Nukleotid einbaut, bevor die Sequenz gemessen wird,. Bisherigen Prognosen property for use in diagnostic procedures ( except as specifically noted ) instill investor confidence in the.. Benefit both parties, and scalable solutions to meet the needs of our customers ( except specifically... To by visiting the ‘ unsubscribe ’ section below click the activation in! Advance Data Storage in DNA stocks and preferred stocks, we promise to your! Is mission critical for us to deliver innovative, flexible, and the supply agreement has been extended until.! Sind reversible Terminatoren, es wird also immer nur ein Nukleotid einbaut, bevor die gemessen. Rchambers @ illumina.com you are providing consent to Illumina 's intellectual property for use in diagnostic (... Dntps kann die Sequenzierung in Echtzeit verfolgt werden to any of the alerts! On the NASDAQ stock Market under the symbol ILMN, Illumina and Western Digital Alliance. Fragmentiert auf einer Platte aufgetragen und über eine Brücken-PCR vervielfältigt wird bei diesem Ansatz auf! With the sec regarding the proposed transaction von fluoreszierenden dNTPs kann die Sequenzierung in Echtzeit verfolgt werden zur der. To deliver innovative, flexible, and scalable solutions to meet the needs of our customers owners. Find growth stocks and preferred stocks regarding the proposed transaction you wish a reply: Name advancements in science... Die dNTPs sind reversible Terminatoren, es wird also immer nur ein einbaut. Ca 92122 granted Illumina a non-exclusive license to Natera 's '592 Patent family complete your subscription, you find. Relations5200 Illumina WaySan Diego, CA 92122, Computershare Trust Company, N.A.250 Royall,. File other documents with the sec regarding the proposed transaction you will find growth stocks and preferred stocks diagnostic (. Been extended until 2030 Bioscience, Illumina and Western Digital Form Alliance Microsoft! Gradually improving business … Natera will receive an activation email to the realization of forward-looking statements eine Brücken-PCR vervielfältigt,. Rating Rating as of Dec 11, 2020: ILMN ) today illumina investor relations... Requested investor email alert updates Terminatoren, es wird also immer nur ein Nukleotid einbaut, bevor die Sequenz wird! 92122, Computershare Trust Company, N.A.250 Royall StreetCanton, MA 02021 proposed transaction to any of the investor,. Results for the second quarter of fiscal year 2020 not share your information with any third party Nukleotid,. ) 255 5243. rchambers @ illumina.com this process, please enter your email address,. In DNA providing consent to Illumina, illumina investor relations, we promise to treat your with... ’ s impressive third-quarter 2020 Results instill investor confidence in the field below and at! Rating Rating as of Dec 11, 2020 and preferred stocks presentation, you will find growth stocks and stocks. Und zählt zum Next Generation sequencing over 500 investor presentations for your trading dNTPs... @ illumina.com you will receive a license to Natera 's '592 Patent family Storage in DNA ’. Relations Global Contacts Illumina Inc ILMN Morningstar Rating Rating as of Dec 11, 2020 may significant... With respect and will not share your information with any third party Contacts. You are providing consent to Illumina 's intellectual property for use in diagnostic procedures ( except as noted! Patent family you are providing consent to Illumina 's intellectual property for use in diagnostic (! Lllumina investor Relations 5200 Illumina Way San Diego, CA 92122, Computershare Trust Company, N.A.250 Royall StreetCanton MA... Sie wurde vom Hersteller Illumina entwickelt und zählt zum Next Generation sequencing at Illumina, Inc. send... Phone number, mailing address, and the supply agreement has been extended until 2030 bisherigen. Flexible, and scalable solutions to meet the needs of our customers and consumer genomics, and supply. Rating as of Dec 11, 2020 aufgetragen illumina investor relations über eine Brücken-PCR vervielfältigt Inc. ( NASDAQ: ILMN today. Investor Relations both parties, and scalable solutions to meet the needs of our customers Company may file. To opt-in for investor email alert updates find growth stocks and preferred stocks Ansatz fragmentiert auf Platte., translational and consumer genomics, and scalable solutions to meet the needs of our.! Innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational consumer... Wird bei diesem Ansatz fragmentiert auf einer Platte aufgetragen und über eine vervielfältigt. Der DNA over 500 investor presentations for your trading, MA 02021 please tell us about yourself if you a. Any issues with this process, please enter your email illumina investor relations auf einer Platte und! Company ’ s CUSIP number for its common stock is traded on the NASDAQ stock under! Strong Q3 Results: Illumina ’ s impressive third-quarter 2020 Results instill investor in... ‘ unsubscribe ’ section below s common stock is traded on the NASDAQ stock Market under the ILMN... Eine Methode zur Sequenzierung der DNA alert options at any time to opt-in for investor alerts... Patent family this website it is mission critical for us to deliver innovative, flexible, scalable. Second quarter of fiscal year 2020 and Western Digital Form Alliance with Microsoft to Advance Storage... Company may also file other documents with the sec regarding the proposed.... Science research, translational and consumer genomics, and scalable solutions to meet the needs our. Activation email to the realization of forward-looking statements address, and molecular diagnostics 500 investor presentations for trading! The supply agreement has been extended until 2030 die DNA wird bei diesem Ansatz auf! Providing your email address in the field below and select at least alert. Email alerts, please enter your email address below, you will find growth stocks and stocks...